Post transplant lymphoproliferative disorder: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 10: | Line 10: | ||
==Historical Perspective== | ==Historical Perspective== | ||
*Post transplant lymphoproliferative disorder was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event]. | *Post transplant lymphoproliferative disorder was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event]. | ||
==Classification== | ==Classification== | ||
*Post transplant lymphoproliferative disorder may be classified according to [classification method] into [number] subtypes/groups: | *Post transplant lymphoproliferative disorder may be classified according to [classification method] into [number] subtypes/groups: | ||
Line 21: | Line 19: | ||
==Pathophysiology== | ==Pathophysiology== | ||
*The pathogenesis of post transplant lymphoproliferative disorder is characterized by | *The pathogenesis of post transplant lymphoproliferative disorder is characterized by: | ||
*The | |||
*On gross pathology, | *The has been associated with the development of post transplant lymphoproliferative disorder. | ||
*On gross pathology, characteristic findings of post transplant lymphoproliferative disorder. | |||
*On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of post transplant lymphoproliferative disorder. | *On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of post transplant lymphoproliferative disorder. | ||
==Causes== | ==Causes== | ||
* | *Common causes of post transplant lymphoproliferative disorder, include: | ||
==Differentiating Post Transplant Lymphoproliferative Disorder from Other Diseases== | |||
==Differentiating | |||
*Post transplant lymphoproliferative disorder must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as: | *Post transplant lymphoproliferative disorder must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as: | ||
:*[Differential dx1] | :*[Differential dx1] | ||
Line 39: | Line 36: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
* The prevalence of post transplant lymphoproliferative disorder is approximately [number or range] per 100,000 individuals worldwide. | * The prevalence of post transplant lymphoproliferative disorder is approximately [number or range] per 100,000 individuals worldwide. | ||
===Age=== | ===Age=== | ||
*Post transplant lymphoproliferative disorder is more commonly observed among patients aged [age range] years old. | *Post transplant lymphoproliferative disorder is more commonly observed among patients aged [age range] years old. | ||
*Post transplant lymphoproliferative disorder is more commonly observed among [elderly patients/young patients/children]. | *Post transplant lymphoproliferative disorder is more commonly observed among [elderly patients/young patients/children]. | ||
Line 49: | Line 42: | ||
===Gender=== | ===Gender=== | ||
*Post transplant lymphoproliferative disorder affects men and women equally. | *Post transplant lymphoproliferative disorder affects men and women equally. | ||
===Race=== | ===Race=== | ||
*There is no racial predilection for post transplant lymphoproliferative disorder. | *There is no racial predilection for post transplant lymphoproliferative disorder. | ||
==Risk Factors== | ==Risk Factors== | ||
*Common risk factors in the development of post transplant lymphoproliferative disorder are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4]. | *Common risk factors in the development of post transplant lymphoproliferative disorder are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4]. | ||
Line 65: | Line 52: | ||
*The majority of patients with post transplant lymphoproliferative disorder remain asymptomatic for [duration/years]. | *The majority of patients with post transplant lymphoproliferative disorder remain asymptomatic for [duration/years]. | ||
*Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3]. | *Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3]. | ||
*If left untreated, | *If left untreated, patients with post transplant lymphoproliferative disorder may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3]. | ||
*Common complications of post transplant lymphoproliferative disorder include [complication 1], [complication 2], and [complication 3]. | *Common complications of post transplant lymphoproliferative disorder include [complication 1], [complication 2], and [complication 3]. | ||
*Prognosis is generally [excellent/good/poor], and the [1/5/10year mortality/survival rate] of patients with post transplant lymphoproliferative disorder is approximately [#%]. | *Prognosis is generally [excellent/good/poor], and the [1/5/10year mortality/survival rate] of patients with post transplant lymphoproliferative disorder is approximately [#%]. | ||
== Diagnosis == | == Diagnosis == | ||
=== Symptoms === | === Symptoms === | ||
*Post transplant lymphoproliferative disorder is usually asymptomatic. | *Post transplant lymphoproliferative disorder is usually asymptomatic. | ||
Line 100: | Line 80: | ||
*There are no specific laboratory findings associated with post transplant lymphoproliferative disorder. | *There are no specific laboratory findings associated with post transplant lymphoproliferative disorder. | ||
===Imaging Findings=== | ===Imaging Findings=== | ||
*There are no | *There are no imaging findings associated with post transplant lymphoproliferative disorder. | ||
== Treatment == | == Treatment == | ||
=== Medical Therapy === | === Medical Therapy === | ||
Line 131: | Line 99: | ||
*There are no primary preventive measures available for post transplant lymphoproliferative disorder. | *There are no primary preventive measures available for post transplant lymphoproliferative disorder. | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category: Oncology ]] | [[Category: Oncology]] |
Revision as of 20:26, 23 May 2016
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Your Name
Synonyms and keywords: Synonym 1; Synonym 2; Synonym 3
Overview
Historical Perspective
- Post transplant lymphoproliferative disorder was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
Classification
- Post transplant lymphoproliferative disorder may be classified according to [classification method] into [number] subtypes/groups:
- [group1]
- [group2]
- [group3]
- Other variants of post transplant lymphoproliferative disorder include [disease subtype 1], [disease subtype 2], and [disease subtype 3].
Pathophysiology
- The pathogenesis of post transplant lymphoproliferative disorder is characterized by:
- The has been associated with the development of post transplant lymphoproliferative disorder.
- On gross pathology, characteristic findings of post transplant lymphoproliferative disorder.
- On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of post transplant lymphoproliferative disorder.
Causes
- Common causes of post transplant lymphoproliferative disorder, include:
Differentiating Post Transplant Lymphoproliferative Disorder from Other Diseases
- Post transplant lymphoproliferative disorder must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
- [Differential dx1]
- [Differential dx2]
- [Differential dx3]
Epidemiology and Demographics
- The prevalence of post transplant lymphoproliferative disorder is approximately [number or range] per 100,000 individuals worldwide.
Age
- Post transplant lymphoproliferative disorder is more commonly observed among patients aged [age range] years old.
- Post transplant lymphoproliferative disorder is more commonly observed among [elderly patients/young patients/children].
Gender
- Post transplant lymphoproliferative disorder affects men and women equally.
Race
- There is no racial predilection for post transplant lymphoproliferative disorder.
Risk Factors
- Common risk factors in the development of post transplant lymphoproliferative disorder are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].
Natural History, Complications and Prognosis
- The majority of patients with post transplant lymphoproliferative disorder remain asymptomatic for [duration/years].
- Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
- If left untreated, patients with post transplant lymphoproliferative disorder may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
- Common complications of post transplant lymphoproliferative disorder include [complication 1], [complication 2], and [complication 3].
- Prognosis is generally [excellent/good/poor], and the [1/5/10year mortality/survival rate] of patients with post transplant lymphoproliferative disorder is approximately [#%].
Diagnosis
Symptoms
- Post transplant lymphoproliferative disorder is usually asymptomatic.
- Symptoms of post transplant lymphoproliferative disorder may include the following:
- [symptom 1]
- [symptom 2]
- [symptom 3]
- [symptom 4]
- [symptom 5]
- [symptom 6]
Physical Examination
- Patients with post transplant lymphoproliferative disorder usually appear [general appearance].
- Physical examination may be remarkable for:
- [finding 1]
- [finding 2]
- [finding 3]
- [finding 4]
- [finding 5]
- [finding 6]
Laboratory Findings
- There are no specific laboratory findings associated with post transplant lymphoproliferative disorder.
Imaging Findings
- There are no imaging findings associated with post transplant lymphoproliferative disorder.
Treatment
Medical Therapy
- There is no treatment for post transplant lymphoproliferative disorder; the mainstay of therapy is supportive care.
- The mainstay of therapy for post transplant lymphoproliferative disorder is [medical therapy 1] and [medical therapy 2].
- [Medical therapy 1] acts by [mechanism of action1].
- Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].
Surgery
- Surgery is the mainstay of therapy for post transplant lymphoproliferative disorder.
- [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of post transplant lymphoproliferative disorder.
- [Surgical procedure] can only be performed for patients with [disease stage] post transplant lymphoproliferative disorder.
Prevention
- There are no primary preventive measures available for post transplant lymphoproliferative disorder.